24-months follow-up to assess the efficacy and tolerability of evolocumab in a young patient with chronic and progressive ischemic arteriopathy. (December 2020) - Rossi, I.; D'Ardes, D.; Vezzani, F.; Guagnano, M.T.; Santilli, F.; Cipollone, F.; Bucci, M.